Polymyxin B and haemofiltration in an adolescent with leukaemia

**J. Scott Baird**

Department of Pediatrics, Division of Critical Care Medicine, Columbia University, New York, NY, USA

*Corresponding author. Present address: Morgan Stanley Children’s Hospital of New York-Presbyterian, 3959 Broadway, CHN 10-24, New York, NY 10032–3784, USA. Tel: +1-212-305-8548; Fax: +1-212-342-2293; E-mail: jsb106@columbia.edu

**Keywords:** clearance, haemofiltration, polymyxin B, sieving coefficient

Sir,

Sandri et al. described the clearance of polymyxin B recently in two patients during continuous venovenous haemodialysis, but data during haemofiltration are not available. An adolescent with relapsed (high-risk) acute lymphocytic leukaemia received a stem cell transplant and developed persistent shock within 24 h. The patient was anuric and received renal replacement therapy (RRT), as well as vasopressors and polymyxin B for presumptive multidrug-resistant, Gram-negative bacterial sepsis. The polymyxin B dose was variable during the first week of RRT due to changing renal function and support. A dose of 100 mg (1 mg/kg/day) polymyxin B by intravenous infusion was given on days 11 and 12 of RRT. On day 13 of RRT (continuous venovenous haemofiltration via a Prismaflex system with an M100 haemofilter and Prismasol BGK 4/2.5 replacement fluid), post-filter (before replacement fluid) and in the ultrafiltrate concentrations of polymyxin B by HPLC drawn pre-filter (after replacement fluid) and in the ultrafiltrate were 123.3, 117.2 and 0 ng/mL, respectively; these levels were measured when the haemofilter had been in use for ~42 h. The extraction ratio was 0.05, the sieving coefficient was 0 and the haemofilter clearance [extraction ratio x blood flow x (1 – haematocrit)] was 8 mL/min; RRT clearance was thus exclusively via haemofilter adsorption. Further data regarding haemofilter sieving and adsorption of polymyxin B are needed.

Columbia University Medical Center’s IRB exempted this report (AAAM4509) from review.

**Funding**

This study was supported by internal funding.

**Transparency declarations**

None to declare.

**References**


J Antimicrob Chemother 2014

doi:10.1093/jac/dkt509

Advance Access publication 19 December 2013

**Darunavir and telaprevir drug interaction: total and unbound plasma concentrations in HIV/HCV-coinfected patients with cirrhosis**

Adrian Curran1*, Josep Maria Guiu2, Esteban Ribera1 and Manuel Crespo1

1Hospital Universitari Vall d’Hebron, Barcelona, Spain; 2Institut de Recerca Vall d’Hebron, Barcelona, Spain

*Corresponding author. Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Passeig Vall d’Hebron 119-129, 08035, Barcelona, Spain. Tel: +34932746090; Fax: +34932746204; E-mail: acurran@vhebron.net

**Keywords:** pharmacokinetics, hepatic cirrhosis, antiretroviral treatment

Sir,

Telaprevir is an NS3/4A protease inhibitor approved for the treatment of chronic hepatitis C virus (HCV) genotype 1. Telaprevir is primarily metabolized by cytochrome 450 3A4 (CYP3A4). Also, telaprevir is a potent inhibitor of CYP3A4 and intestinal P-glycoprotein, resulting in increased concentrations of CYP3A substrates. Darunavir is mainly metabolized by CYP450 and ritonavir is a potent CYP450 inhibitor. Significant drug–drug interactions have been described in healthy volunteers between telaprevir (750 mg/8 h) and darunavir/ritonavir (600/100 mg/12 h), resulting in decreases in plasma concentrations of both drugs (darunavir: Cmax = −40%, AUC = −40% and Cmin = −42%; telaprevir: Cmax = −36%, AUC = −35% and Cmin = −32%).

Based on these data, co-administration of darunavir/ritonavir and telaprevir is not recommended. However, a darunavir/